BRED Life Exhibited at the 42nd ESHRE

From July 5th to July 8th, 2026, the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE 2026) was grandly held in London, UK. As one of the largest and highest - level international events in the global reproductive medicine field, this year's congress gathered top experts, scholars, and industry representatives from more than 150 countries and regions around the world. They conducted in - depth exchanges and discussions on cutting - edge technologies in reproductive medicine, breakthroughs in clinical applications, and industry development trends. BRED Life participated in the congress with its core technologies and innovative solutions, demonstrating China's R & D strength and innovation achievements in the field of assisted reproduction to the world.

Deeply Engaged in Technological Innovation to Promote High - Quality Development of Reproductive Medicine The ESHRE Annual Meeting has always centered on promoting scientific progress and clinical practice in the field of reproductive health. Each session presents the most breakthrough research progress and technological applications globally. BRED has been deeply involved in the field of reproductive medicine for many years, always adhering to the concept of "Protecting the Beginning of Life with Technology". It focuses on the R & D and industrialization of male infertility diagnosis, detection reagents related to assisted reproduction, supporting equipment, and overall solutions. During this congress, the company mainly showcased its self - developed series of seminal plasma biochemical and immunological analysis, series of sperm function flow cytometry detection, series of reproductive culture optimization, as well as key products such as sperm DNA fragmentation and sperm hyaluronic acid binding test. Relying on advanced production processes and high - quality imported raw materials, the company's products have reached international advanced standards in terms of stability, accuracy, and safety. They can effectively assist clinical diagnosis of the causes of male infertility and improve the success rate of assisted reproduction treatments, providing more reliable technical support for global reproductive centers.

Deepening International Exchanges and Expanding New Dimensions of Industry Cooperation At the exhibition site, BRED's booth attracted many international experts, representatives of medical institutions, and partners to stop for exchanges. The team members had in - depth discussions with peers from various countries on topics such as technical principles, clinical application data, and product optimization directions. They carefully listened to international cutting - edge concepts and clinical feedback and also shared the experience of Chinese enterprises in R & D and practice. Through participating in this congress, BRED further strengthened its connection with the global reproductive medicine field. It not only expanded international cooperation channels but also accumulated valuable international perspectives for subsequent technological iteration and product upgrading. The relevant person - in - charge of the company believes that ESHRE is an important communication platform in the global reproductive field. "We hope to use this window to let more international peers know about China's technologies and products. By learning advanced experience, we can continuously improve our own capabilities and contribute Chinese strength to the global reproductive health cause."

Upholding the Original Mission and Moving towards a Higher Development Stage This appearance at ESHRE 2026 is not only the international market's recognition of BRED's technical strength but also an important step for the company to deepen its international development. In the future, Boraide will continue to uphold the original intention of scientific and technological innovation, increase R & D investment, focus on solving practical clinical needs, continuously improve the product portfolio and service system. At the same time, it will actively participate in international academic exchanges and cooperation, promote more high - quality and efficient reproductive medicine technologies to the world, and continue to move forward to protect life conception and improve the global reproductive health level.